Semanteon Capital Management LP Takes $686,000 Position in Harrow, Inc. (NASDAQ:HROW)

Semanteon Capital Management LP purchased a new position in Harrow, Inc. (NASDAQ:HROW - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 15,257 shares of the company's stock, valued at approximately $686,000.

Other hedge funds have also made changes to their positions in the company. nVerses Capital LLC acquired a new position in Harrow during the 2nd quarter valued at about $33,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company's stock valued at $44,000 after buying an additional 2,048 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock worth $57,000 after buying an additional 227 shares during the period. Bayesian Capital Management LP bought a new position in Harrow in the 1st quarter worth approximately $185,000. Finally, Price T Rowe Associates Inc. MD increased its position in Harrow by 6.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company's stock valued at $221,000 after acquiring an additional 1,033 shares during the period. Institutional investors own 72.76% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Lake Street Capital boosted their price target on Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a research report on Friday, October 4th. Craig Hallum upped their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a report on Friday, October 4th. Finally, B. Riley reissued a "buy" rating and set a $50.00 target price on shares of Harrow in a research note on Thursday, August 29th.

Harrow Price Performance

NASDAQ HROW traded down $0.65 on Tuesday, reaching $46.55. 594,203 shares of the stock traded hands, compared to its average volume of 497,825. Harrow, Inc. has a 12 month low of $7.60 and a 12 month high of $59.23. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18. The firm's fifty day simple moving average is $46.08 and its 200 day simple moving average is $29.02. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -48.22 and a beta of 0.75.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.12. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. The firm had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. As a group, research analysts predict that Harrow, Inc. will post 0.09 EPS for the current fiscal year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.